David Venables
Chief Executive Officer at Synpromics Ltd.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Michael L. Roberts | M | - |
Synpromics Ltd.
 Synpromics Ltd. Chemicals: SpecialtyProcess Industries Synpromics Ltd. develops and commercializes synthetic promoters to control gene expressions and regulations. The firm is active in cell and gene therapy, biologics bioprocessing, and industrial biotechnology. The company was founded by Michael L. Robert in 2010 and is headquartered in Edinburgh, the United Kingdom. | - |
| Elsy Boglioli Hofman | F | 42 |
Laverock Therapeutics Ltd.
 Laverock Therapeutics Ltd. Pharmaceuticals: OtherHealth Technology Laverock Therapeutics Ltd. develops regenerative medicines for hypo immune pancreatic islet cells and oncology therapeutics. The CEO of the British company is David C. Venables. | - |
| Erez Vigodman | M | 64 |
Laverock Therapeutics Ltd.
Laverock Therapeutics Ltd. Pharmaceuticals: OtherHealth Technology Laverock Therapeutics Ltd. develops regenerative medicines for hypo immune pancreatic islet cells and oncology therapeutics. The CEO of the British company is David C. Venables. | - |
| John Brown | M | 69 |
Laverock Therapeutics Ltd.
Laverock Therapeutics Ltd. Pharmaceuticals: OtherHealth Technology Laverock Therapeutics Ltd. develops regenerative medicines for hypo immune pancreatic islet cells and oncology therapeutics. The CEO of the British company is David C. Venables. | - |
| Gilad Gershon | M | - |
Laverock Therapeutics Ltd.
Laverock Therapeutics Ltd. Pharmaceuticals: OtherHealth Technology Laverock Therapeutics Ltd. develops regenerative medicines for hypo immune pancreatic islet cells and oncology therapeutics. The CEO of the British company is David C. Venables. | - |
| Ken Macnamara | M | - |
Synpromics Ltd.
Synpromics Ltd. Chemicals: SpecialtyProcess Industries Synpromics Ltd. develops and commercializes synthetic promoters to control gene expressions and regulations. The firm is active in cell and gene therapy, biologics bioprocessing, and industrial biotechnology. The company was founded by Michael L. Robert in 2010 and is headquartered in Edinburgh, the United Kingdom. | - |
| Tom Payne | M | - |
Laverock Therapeutics Ltd.
Laverock Therapeutics Ltd. Pharmaceuticals: OtherHealth Technology Laverock Therapeutics Ltd. develops regenerative medicines for hypo immune pancreatic islet cells and oncology therapeutics. The CEO of the British company is David C. Venables. | 3 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Martyn D. Williams | M | - |
Ark Therapeutics Group Plc
 Ark Therapeutics Group Plc Miscellaneous Commercial ServicesCommercial Services Ark Therapeutics Group Plc is a gene-based medicine company, which is engaged in the discovery, development and commercialization of products in areas of specialist medicine, with particular focus on vascular disease and cancer. The company was founded by Peter Stephen Keen, John W. Martin, Seppo Ylä-Herttuala, Stephen Barker and Kenneth Powell in July 1997 and is headquartered in London, the United Kingdom. | 14 years |
| Seppo Ylä-Herttuala | M | - |
Ark Therapeutics Group Plc
Ark Therapeutics Group Plc Miscellaneous Commercial ServicesCommercial Services Ark Therapeutics Group Plc is a gene-based medicine company, which is engaged in the discovery, development and commercialization of products in areas of specialist medicine, with particular focus on vascular disease and cancer. The company was founded by Peter Stephen Keen, John W. Martin, Seppo Ylä-Herttuala, Stephen Barker and Kenneth Powell in July 1997 and is headquartered in London, the United Kingdom. | 16 years |
| Tracie Elizabeth Ramsdale | M | 62 | 6 years | |
| David James Stuart Hetzel | M | - | 4 years | |
| Dominic Tonner | M | 67 |
Ark Therapeutics Group Plc
Ark Therapeutics Group Plc Miscellaneous Commercial ServicesCommercial Services Ark Therapeutics Group Plc is a gene-based medicine company, which is engaged in the discovery, development and commercialization of products in areas of specialist medicine, with particular focus on vascular disease and cancer. The company was founded by Peter Stephen Keen, John W. Martin, Seppo Ylä-Herttuala, Stephen Barker and Kenneth Powell in July 1997 and is headquartered in London, the United Kingdom. | - |
| Charles Spicer | M | 59 |
Ark Therapeutics Group Plc
Ark Therapeutics Group Plc Miscellaneous Commercial ServicesCommercial Services Ark Therapeutics Group Plc is a gene-based medicine company, which is engaged in the discovery, development and commercialization of products in areas of specialist medicine, with particular focus on vascular disease and cancer. The company was founded by Peter Stephen Keen, John W. Martin, Seppo Ylä-Herttuala, Stephen Barker and Kenneth Powell in July 1997 and is headquartered in London, the United Kingdom. | 2 years |
| Peter Stephen Keen | M | 66 |
Ark Therapeutics Group Plc
Ark Therapeutics Group Plc Miscellaneous Commercial ServicesCommercial Services Ark Therapeutics Group Plc is a gene-based medicine company, which is engaged in the discovery, development and commercialization of products in areas of specialist medicine, with particular focus on vascular disease and cancer. The company was founded by Peter Stephen Keen, John W. Martin, Seppo Ylä-Herttuala, Stephen Barker and Kenneth Powell in July 1997 and is headquartered in London, the United Kingdom. | 15 years |
| David Philip Bloxham | M | - |
Ark Therapeutics Group Plc
Ark Therapeutics Group Plc Miscellaneous Commercial ServicesCommercial Services Ark Therapeutics Group Plc is a gene-based medicine company, which is engaged in the discovery, development and commercialization of products in areas of specialist medicine, with particular focus on vascular disease and cancer. The company was founded by Peter Stephen Keen, John W. Martin, Seppo Ylä-Herttuala, Stephen Barker and Kenneth Powell in July 1997 and is headquartered in London, the United Kingdom. | 4 years |
| Rajan Uppal | M | 62 |
Ark Therapeutics Group Plc
Ark Therapeutics Group Plc Miscellaneous Commercial ServicesCommercial Services Ark Therapeutics Group Plc is a gene-based medicine company, which is engaged in the discovery, development and commercialization of products in areas of specialist medicine, with particular focus on vascular disease and cancer. The company was founded by Peter Stephen Keen, John W. Martin, Seppo Ylä-Herttuala, Stephen Barker and Kenneth Powell in July 1997 and is headquartered in London, the United Kingdom. | - |
| David Prince | M | 73 |
Ark Therapeutics Group Plc
Ark Therapeutics Group Plc Miscellaneous Commercial ServicesCommercial Services Ark Therapeutics Group Plc is a gene-based medicine company, which is engaged in the discovery, development and commercialization of products in areas of specialist medicine, with particular focus on vascular disease and cancer. The company was founded by Peter Stephen Keen, John W. Martin, Seppo Ylä-Herttuala, Stephen Barker and Kenneth Powell in July 1997 and is headquartered in London, the United Kingdom. | 9 years |
| Gareth Jones | M | - |
University of Surrey
| 8 years |
| Daniel Smith | M | - |
Ark Therapeutics Group Plc
Ark Therapeutics Group Plc Miscellaneous Commercial ServicesCommercial Services Ark Therapeutics Group Plc is a gene-based medicine company, which is engaged in the discovery, development and commercialization of products in areas of specialist medicine, with particular focus on vascular disease and cancer. The company was founded by Peter Stephen Keen, John W. Martin, Seppo Ylä-Herttuala, Stephen Barker and Kenneth Powell in July 1997 and is headquartered in London, the United Kingdom. | - |
| Jeremy Burton | M | 56 |
University of Surrey
| 4 years |
| Wei Sun | M | 64 |
University of Surrey
| 3 years |
| Damian Wilson | M | - | - | |
| Paul Grujic | M | - | 3 years | |
| Robert Passas | M | 71 |
University of Surrey
| 3 years |
| Jonathan Cornes | M | - |
University of Surrey
| 4 years |
| Wing Fai Leung | M | 63 |
University of Surrey
| 4 years |
| Mochamad Harry Jaya Pahlawan | M | 67 |
University of Surrey
| 1 years |
| Cheung Ming Chan | M | 70 |
University of Surrey
| 3 years |
| Aamer Adamjee | M | - |
University of Surrey
| 4 years |
| Iek Cruyningen | M | - |
University of Surrey
| 4 years |
| Andrew White | M | - |
University of Surrey
| 1 years |
| Philip Taylor | M | 57 |
University of Surrey
| 2 years |
| Steve Chilton | M | - |
University of Surrey
| 3 years |
| Alex J. Sinaga | M | 62 |
University of Surrey
| 1 years |
| Kassim Kolia | M | - |
Ark Therapeutics Group Plc
Ark Therapeutics Group Plc Miscellaneous Commercial ServicesCommercial Services Ark Therapeutics Group Plc is a gene-based medicine company, which is engaged in the discovery, development and commercialization of products in areas of specialist medicine, with particular focus on vascular disease and cancer. The company was founded by Peter Stephen Keen, John W. Martin, Seppo Ylä-Herttuala, Stephen Barker and Kenneth Powell in July 1997 and is headquartered in London, the United Kingdom. | - |
| Kok Cheong Wong | M | - |
University of Surrey
| 3 years |
| Ioannis Mertzanis | M | 58 |
University of Surrey
| 1 years |
| Richard Creitzman | M | - |
University of Surrey
| 4 years |
| Ashley Lane | M | 55 |
University of Surrey
| 1 years |
| Seong-Dong Park | M | 57 |
University of Surrey
| 1 years |
| Robert A. Ollar | M | - |
University of Surrey
| 3 years |
| Arief Yahya | M | 63 |
University of Surrey
| 1 years |
| Gill Slater | F | - |
University of Surrey
| 4 years |
| Ken Pryde | M | - |
University of Surrey
| 2 years |
| Iain Ross | M | 71 |
Ark Therapeutics Group Plc
Ark Therapeutics Group Plc Miscellaneous Commercial ServicesCommercial Services Ark Therapeutics Group Plc is a gene-based medicine company, which is engaged in the discovery, development and commercialization of products in areas of specialist medicine, with particular focus on vascular disease and cancer. The company was founded by Peter Stephen Keen, John W. Martin, Seppo Ylä-Herttuala, Stephen Barker and Kenneth Powell in July 1997 and is headquartered in London, the United Kingdom. | 5 years |
| Adrian Lee | M | - |
University of Surrey
| 3 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United Kingdom | 42 | 91.30% |
| Australia | 4 | 8.70% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- David Venables
- Personal Network
